Cargando…

Perfusion-CT monitoring of cryo-ablated renal cells tumors

BACKGROUND: No single and thoroughly validated imaging method in monitoring of cryoablated renal cell carcinoma (RCC) is available. The purpose of our study was to determine the feasibility of dynamic contrast-enhanced perfusion CT (pCT) in evaluating the hemodynamic response of RCC. METHODS: 15 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Squillaci, Ettore, Manenti, Guglielmo, Cicciò, Carmelo, Nucera, Francesca, Bove, Pierluigi, Vespasiani, Giuseppe, Russolillo, Laura, Simonetti, Giovanni
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763857/
https://www.ncbi.nlm.nih.gov/pubmed/19818144
http://dx.doi.org/10.1186/1756-9966-28-138
_version_ 1782173043620052992
author Squillaci, Ettore
Manenti, Guglielmo
Cicciò, Carmelo
Nucera, Francesca
Bove, Pierluigi
Vespasiani, Giuseppe
Russolillo, Laura
Simonetti, Giovanni
author_facet Squillaci, Ettore
Manenti, Guglielmo
Cicciò, Carmelo
Nucera, Francesca
Bove, Pierluigi
Vespasiani, Giuseppe
Russolillo, Laura
Simonetti, Giovanni
author_sort Squillaci, Ettore
collection PubMed
description BACKGROUND: No single and thoroughly validated imaging method in monitoring of cryoablated renal cell carcinoma (RCC) is available. The purpose of our study was to determine the feasibility of dynamic contrast-enhanced perfusion CT (pCT) in evaluating the hemodynamic response of RCC. METHODS: 15 patients (14 male, 1 female; age range, 43-81 years; mean age, 62 years) with cryoablated RCC via a transperitoneal approach, underwent to pCT 6-8 months after cryo-therapy. pCT was performed for 65 seconds after intravenous injection of contrast medium (80 mL, 370 mg iodine per millilitre, 4 mL/sec). Perfusion parameters (Time/Density curve; Blood flow, BF; Blood Volume, BV; Mean Transit Time, MTT; Permeability-Surface Area Product, PS) were sampled in the cryoablated tumor area and in ipsilateral renal cortex using deconvolution-based method. A tumor was considered to be not responsive to treatment by CT evidence of pathological contrast enhancement in the cryoablated area or renal mass persistence compared with the preoperative CT control. Written informed consent was obtained from all participants before the study. RESULTS: After cryotherapy, successfully ablated tumor (n = 13) showed decrease in BV (5,39 +/- 1,28 mL/100 g), BF (69,92 +/- 20,12 mL/100 g/min) and PS (16,66 +/- 5,67 mL/100 g/min) value and increased value of MTT (25,35 +/- 4,3 sec) compared with those of normal renal cortex (BV: 117,86 +/- 31,87 mL/100 g/min; BF: 392,39 +/- 117,32 mL/100 g/min; MTT: 18,02 +/- 3,6 sec; PS: 81,68 +/- 22,75 mL/100 g/min). In one patient, assessment of perfusion parameters was not feasible for breathing artifacts. One tumor showed poor response to treatment by the evidence of nodular contrast enhancement in the region encompassing the original lesion. Two typical enhancement patterns were obtained comparing the Time-Density curves of responsive and not responsive ablated tumors. CONCLUSION: Perfusion CT seems to be a feasible and promising technique in monitoring the effects of cryoablation therapy.
format Text
id pubmed-2763857
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27638572009-10-20 Perfusion-CT monitoring of cryo-ablated renal cells tumors Squillaci, Ettore Manenti, Guglielmo Cicciò, Carmelo Nucera, Francesca Bove, Pierluigi Vespasiani, Giuseppe Russolillo, Laura Simonetti, Giovanni J Exp Clin Cancer Res Research BACKGROUND: No single and thoroughly validated imaging method in monitoring of cryoablated renal cell carcinoma (RCC) is available. The purpose of our study was to determine the feasibility of dynamic contrast-enhanced perfusion CT (pCT) in evaluating the hemodynamic response of RCC. METHODS: 15 patients (14 male, 1 female; age range, 43-81 years; mean age, 62 years) with cryoablated RCC via a transperitoneal approach, underwent to pCT 6-8 months after cryo-therapy. pCT was performed for 65 seconds after intravenous injection of contrast medium (80 mL, 370 mg iodine per millilitre, 4 mL/sec). Perfusion parameters (Time/Density curve; Blood flow, BF; Blood Volume, BV; Mean Transit Time, MTT; Permeability-Surface Area Product, PS) were sampled in the cryoablated tumor area and in ipsilateral renal cortex using deconvolution-based method. A tumor was considered to be not responsive to treatment by CT evidence of pathological contrast enhancement in the cryoablated area or renal mass persistence compared with the preoperative CT control. Written informed consent was obtained from all participants before the study. RESULTS: After cryotherapy, successfully ablated tumor (n = 13) showed decrease in BV (5,39 +/- 1,28 mL/100 g), BF (69,92 +/- 20,12 mL/100 g/min) and PS (16,66 +/- 5,67 mL/100 g/min) value and increased value of MTT (25,35 +/- 4,3 sec) compared with those of normal renal cortex (BV: 117,86 +/- 31,87 mL/100 g/min; BF: 392,39 +/- 117,32 mL/100 g/min; MTT: 18,02 +/- 3,6 sec; PS: 81,68 +/- 22,75 mL/100 g/min). In one patient, assessment of perfusion parameters was not feasible for breathing artifacts. One tumor showed poor response to treatment by the evidence of nodular contrast enhancement in the region encompassing the original lesion. Two typical enhancement patterns were obtained comparing the Time-Density curves of responsive and not responsive ablated tumors. CONCLUSION: Perfusion CT seems to be a feasible and promising technique in monitoring the effects of cryoablation therapy. BioMed Central 2009-10-10 /pmc/articles/PMC2763857/ /pubmed/19818144 http://dx.doi.org/10.1186/1756-9966-28-138 Text en Copyright © 2009 Squillaci et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Squillaci, Ettore
Manenti, Guglielmo
Cicciò, Carmelo
Nucera, Francesca
Bove, Pierluigi
Vespasiani, Giuseppe
Russolillo, Laura
Simonetti, Giovanni
Perfusion-CT monitoring of cryo-ablated renal cells tumors
title Perfusion-CT monitoring of cryo-ablated renal cells tumors
title_full Perfusion-CT monitoring of cryo-ablated renal cells tumors
title_fullStr Perfusion-CT monitoring of cryo-ablated renal cells tumors
title_full_unstemmed Perfusion-CT monitoring of cryo-ablated renal cells tumors
title_short Perfusion-CT monitoring of cryo-ablated renal cells tumors
title_sort perfusion-ct monitoring of cryo-ablated renal cells tumors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763857/
https://www.ncbi.nlm.nih.gov/pubmed/19818144
http://dx.doi.org/10.1186/1756-9966-28-138
work_keys_str_mv AT squillaciettore perfusionctmonitoringofcryoablatedrenalcellstumors
AT manentiguglielmo perfusionctmonitoringofcryoablatedrenalcellstumors
AT cicciocarmelo perfusionctmonitoringofcryoablatedrenalcellstumors
AT nucerafrancesca perfusionctmonitoringofcryoablatedrenalcellstumors
AT bovepierluigi perfusionctmonitoringofcryoablatedrenalcellstumors
AT vespasianigiuseppe perfusionctmonitoringofcryoablatedrenalcellstumors
AT russolillolaura perfusionctmonitoringofcryoablatedrenalcellstumors
AT simonettigiovanni perfusionctmonitoringofcryoablatedrenalcellstumors